Tag:
melanoma
Latest Headlines
Latest Headlines
Carbohydrate, vaccine combination could push melanoma immunotherapy forward
Galectin Therapeutics has started treating patients with advanced disease in a Phase I/II trial to see if combining its galectin inhibitor GM-CT-01 with a peptide-based cancer vaccine developed at the Ludwig institute improves the outcome of patients with advanced metastatic melanoma.
'Designer' lymph nodes could boost cancer vaccines
Researchers at the Moffitt Cancer Center are developing "designer" lymph nodes that could be used to boost the effects of cancer vaccines.
Scancell's DNA melanoma vaccine poised for Phase II
Scancell, a U.K. spinout from the University of Nottingham, has completed recruitment for the Phase I trial of SCIB1, its therapeutic DNA vaccine for the treatment of melanoma.
Genoptix test to guide melanoma treatment decisions
Personalized medicine has been a popular topic in medical device and biopharma circles as of late. One company that has long had its eye on this area is Genoptix Medical Laboratory.
Mayo Clinic concocts skin cancer vaccine using virus, melanoma DNA
Mayo Clinic scientists essentially used cancer cells to boost the immune system's response in order to kill cancer.
Prostate cancer vaccine teams up with antibody
Sometimes, the sum of the parts is greater than the whole, and this can be true for cancer therapies as well. Researchers are hoping that combining Prostvac, the investigational therapeutic cancer...
Adding MEK drug to Zelboraf could stymie secondary cancers
When Roche 's melanoma drug Zelboraf won the FDA nod in August, it became the first therapy for the disease targeted at patients with a particular genetic abnormality. Scientists now have found
Roche melanoma drug wins early FDA nod
The FDA came through with an early approval for Roche's new melanoma drug Zelboraf and the diagnostic test that targets it. The drug works on patients with a BRAF mutation, which amounts to about
Yervoy may face Roche rival sooner than expected
Roche's new melanoma treatment, dubbed Zelboraf, may get an early entry into the market. Sources tell Reuters the experimental drug could be approved as early as next week, months ahead of schedule.
Yervoy hits the market with $95M bang
Market watchers expected Bristol-Myers Squibb's ($BMY) new cancer drug to be big, but this fast? The company's second-quarter sales left Wall Street estimates in the dust and prompted an increase in
